MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 326998 | Name: Revefenacin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

This product is discontinued for commercial reason.

Chemical Structure

Revefenacin
Revefenacin
CAS#864750-70-9 (free base)

Theoretical Analysis

MedKoo Cat#: 326998

Name: Revefenacin

CAS#: 864750-70-9 (free base)

Chemical Formula: C35H43N5O4

Exact Mass: 597.3315

Molecular Weight: 597.76

Elemental Analysis: C, 70.33; H, 7.25; N, 11.72; O, 10.71

Price and Availability

This product was removed for the commercial reasons.
Related CAS #
864750-70-9 (free base) 864751-51-9 (phosphate) 864751-53-1 (sulfate) 864751-55-3 (oxalate)
Synonym
Revefenacin; TD-4208; TD 4208; TD4208; GSK-1160724; GSK1160724; GSK 1160724; Yupelri.
IUPAC/Chemical Name
1-(2-(4-((4-Carbamoylpiperidin-1-yl)methyl)-N-methylbenzamido)ethyl)piperidin-4-yl N-((1,1'-biphenyl)-2-yl)carbamate
InChi Key
FYDWDCIFZSGNBU-UHFFFAOYSA-N
InChi Code
InChI=1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43)
SMILES Code
O=C(OC1CCN(CCN(C)C(C2=CC=C(CN3CCC(C(N)=O)CC3)C=C2)=O)CC1)NC4=CC=CC=C4C5=CC=CC=C5
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 597.76 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Clark CM, Jacobs DM, Sethi S. Revefenacin for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2019 Dec 17. doi: 10.1080/17476348.2020.1703676. [Epub ahead of print] PubMed PMID: 31847629. 2: Lal C, Khan A. Emerging Treatments for COPD: Evidence to Date on Revefenacin. COPD. 2019 Dec 13:1-8. doi: 10.1080/15412555.2019.1702010. [Epub ahead of print] PubMed PMID: 31833419. 3: Donohue JF, Kerwin E, Sethi S, Haumann B, Pendyala S, Dean L, Barnes CN, Moran EJ, Crater G. Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD). Respir Res. 2019 Oct 30;20(1):241. doi: 10.1186/s12931-019-1187-7. PubMed PMID: 31666076; PubMed Central PMCID: PMC6822411. 4: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548918/ PubMed PMID: 31644224. 5: Borin MT, Lo A, Barnes CN, Pendyala S, Bourdet DL. Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function. Int J Chron Obstruct Pulmon Dis. 2019 Oct 8;14:2305-2318. doi: 10.2147/COPD.S203709. eCollection 2019. PubMed PMID: 31632000; PubMed Central PMCID: PMC6790214. 6: Donohue J, Kerwin E, Sethi S, Haumann B, Pendyala S, Dean L, Barnes CN, Moran EJ, Crater G. Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease. Data Brief. 2019 Aug 22;26:104277. doi: 10.1016/j.dib.2019.104277. eCollection 2019 Oct. PubMed PMID: 31534988; PubMed Central PMCID: PMC6744553. 7: Borin MT, Barnes CN, Darpo B, Pendyala S, Xue H, Bourdet DL. Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study. Clin Pharmacol Drug Dev. 2019 Aug 29. doi: 10.1002/cpdd.732. [Epub ahead of print] PubMed PMID: 31468714. 8: Maqsood MH, Rubab K, Maqsood MA. The Role of Revefenacin in Chronic Obstructive Pulmonary Disease. Cureus. 2019 Apr 10;11(4):e4428. doi: 10.7759/cureus.4428. Review. PubMed PMID: 31245215; PubMed Central PMCID: PMC6559386. 9: Donohue JF, Feldman G, Sethi S, Barnes CN, Pendyala S, Bourdet D, Crater G. Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials. Pulm Pharmacol Ther. 2019 Aug;57:101808. doi: 10.1016/j.pupt.2019.101808. Epub 2019 May 30. PubMed PMID: 31152911. 10: Donohue JF, Kerwin E, Sethi S, Haumann B, Pendyala S, Dean L, Barnes CN, Moran EJ, Crater G. Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease. Respir Med. 2019 Jul;153:38-43. doi: 10.1016/j.rmed.2019.05.010. Epub 2019 May 23. PubMed PMID: 31150963. 11: Hussar DA, Meisel AH. Sodium zirconium cyclosilicate, Revefenacin, and Cannabidiol. J Am Pharm Assoc (2003). 2019 May - Jun;59(3):451-455. doi: 10.1016/j.japh.2019.04.001. PubMed PMID: 31101315. 12: Ferguson GT, Feldman G, Pudi KK, Barnes CN, Moran EJ, Haumann B, Pendyala S, Crater G. Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials. Chronic Obstr Pulm Dis. 2019 Apr 9;6(2):154-165. doi: 10.15326/jcopdf.6.2.2018.0152. Epub 2019 Apr 9. PubMed PMID: 30974049; PubMed Central PMCID: PMC6596436. 13: Heo YA. Correction to: Revefenacin: First Global Approval. Drugs. 2019 Apr;79(6):689. doi: 10.1007/s40265-019-01106-z. PubMed PMID: 30927162; PubMed Central PMCID: PMC6483947. 14: Revefenacin (Yupelri) for COPD. Med Lett Drugs Ther. 2019 Jan 28;61(1564):14-15. Review. PubMed PMID: 30856160. 15: Li F, Yang J. Revefenacin for the treatment of chronic obstructive pulmonary disease. Expert Rev Clin Pharmacol. 2019 Apr;12(4):293-298. doi: 10.1080/17512433.2019.1587292. Epub 2019 Mar 22. Review. PubMed PMID: 30803279. 16: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK535607/ PubMed PMID: 30601616. 17: Heo YA. Revefenacin: First Global Approval. Drugs. 2019 Jan;79(1):85-91. doi: 10.1007/s40265-018-1036-x. Review. Erratum in: Drugs. 2019 Mar 29;:. PubMed PMID: 30560478; PubMed Central PMCID: PMC6445810. 18: Hegde SS, Pulido-Rios MT, Luttmann MA, Foley JJ, Hunsberger GE, Steinfeld T, Lee T, Ji Y, Mammen MM, Jasper JR. Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues. Pharmacol Res Perspect. 2018 Apr 30;6(3):e00400. doi: 10.1002/prp2.400. eCollection 2018 Jun. PubMed PMID: 29736245; PubMed Central PMCID: PMC5927803. 19: Pudi KK, Barnes CN, Moran EJ, Haumann B, Kerwin E. A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease. Respir Res. 2017 Nov 2;18(1):182. doi: 10.1186/s12931-017-0647-1. PubMed PMID: 29096627; PubMed Central PMCID: PMC5667509. 20: Quinn D, Barnes CN, Yates W, Bourdet DL, Moran EJ, Potgieter P, Nicholls A, Haumann B, Singh D. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies. Pulm Pharmacol Ther. 2018 Feb;48:71-79. doi: 10.1016/j.pupt.2017.10.003. Epub 2017 Oct 4. PubMed PMID: 28987804.